-
EP3518931
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3518931
| EP3518931 - METHOD FOR TREATING CANCER USING A COMBINATION OF DNA-DAMAGING AGENTS AND DNA-PK INHIBITORS [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 03.02.2023 Database last updated on 19.10.2024 | |
| Former | Request for examination was made Status updated on 05.07.2019 | ||
| Former | The international publication has been made Status updated on 07.04.2018 | Most recent event Tooltip | 28.09.2024 | New entry: Renewal fee paid | Applicant(s) | For all designated states Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston, MA 02210 / US | [2019/32] | Inventor(s) | 01 /
BOUCHER, Diane M. c/o Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston Massachusetts 02210 / US | 02 /
HILLIER, Shawn M. c/o Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston Massachusetts 02210 / US | 03 /
TSAI, Wanjung c/o Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston Massachusetts 02210 / US | 04 /
HARE, Brian c/o Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston Massachusetts 02210 / US | 05 /
MARKLAND, William c/o Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston Massachusetts 02210 / US | 06 /
NEWSOME, David A. c/o Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston Massachusetts 02210 / US | 07 /
PENNEY, Marina S. c/o Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston Massachusetts 02210 / US | [2019/32] | Representative(s) | Tostmann, Holger Carl Wallinger Ricker Schlotter Tostmann Patent- und Rechtsanwälte Partnerschaft mbB Zweibrückenstrasse 5-7 80331 München / DE | [2019/32] | Application number, filing date | 17857298.8 | 27.09.2017 | [2019/32] | WO2017US53589 | Priority number, date | US201662400606P | 27.09.2016 Original published format: US 201662400606 P | US201662497943P | 08.12.2016 Original published format: US 201662497943 P | [2019/32] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2018064092 | Date: | 05.04.2018 | Language: | EN | [2018/14] | Type: | A1 Application with search report | No.: | EP3518931 | Date: | 07.08.2019 | Language: | EN | The application published by WIPO in one of the EPO official languages on 05.04.2018 takes the place of the publication of the European patent application. | [2019/32] | Search report(s) | International search report - published on: | US | 05.04.2018 | (Supplementary) European search report - dispatched on: | EP | 17.04.2020 | Classification | IPC: | A61K31/506, C07D401/14, C07B59/00, A61P35/00 | [2020/20] | CPC: |
A61K45/06 (EP,IL,KR);
A61K31/506 (EP,IL,KR,RU);
A61K31/704 (EP,IL,KR,RU,US);
A61K31/7048 (EP,IL);
A61K9/1271 (EP,IL,KR,US);
A61P35/00 (EP,KR,RU,US);
A61P43/00 (EP);
C07D401/14 (EP,IL,KR,US);
C07D403/14 (EP,IL,KR,US);
| C-Set: |
A61K31/506, A61K2300/00 (EP);
A61K31/7048, A61K2300/00 (EP);
A61K31/704, A61K2300/00 (EP)
|
| Former IPC [2019/32] | A61K31/506, C07D401/14, C07B59/00 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2019/32] | Title | German: | VERFAHREN ZUR BEHANDLUNG VON KREBS MIT EINER KOMBINATION AUS DNA-SCHÄDIGENDEN SUBSTANZEN UND DNA-PK-INHIBITOREN | [2019/32] | English: | METHOD FOR TREATING CANCER USING A COMBINATION OF DNA-DAMAGING AGENTS AND DNA-PK INHIBITORS | [2019/32] | French: | MÉTHODE DE TRAITEMENT DU CANCER UTILISANT UNE COMBINAISON D'AGENTS ENDOMMAGEANT L'ADN ET D'INHIBITEURS DE LA DNA-PK | [2019/32] | Entry into regional phase | 15.03.2019 | National basic fee paid | 15.03.2019 | Search fee paid | 15.03.2019 | Designation fee(s) paid | 15.03.2019 | Examination fee paid | Examination procedure | 15.03.2019 | Examination requested [2019/32] | 11.11.2020 | Amendment by applicant (claims and/or description) | 07.02.2023 | Despatch of a communication from the examining division (Time limit: M04) | 03.05.2023 | Reply to a communication from the examining division | Fees paid | Renewal fee | 27.09.2019 | Renewal fee patent year 03 | 28.09.2020 | Renewal fee patent year 04 | 27.09.2021 | Renewal fee patent year 05 | 27.09.2022 | Renewal fee patent year 06 | 27.09.2023 | Renewal fee patent year 07 | 27.09.2024 | Renewal fee patent year 08 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [IY]WO2006126010 (KUDOS PHARM LTD [GB], et al) [I] 1-7,12-14 * claims 1-27 * * page 50, lines 4-10 * [Y] 8-11; | [IY]WO2015058067 (VERTEX PHARMA [US]) [I] 1-14 * the whole document *[Y] 8-11; | [IY]WO2016014148 (MAYO FOUNDATION [US]) [I] 1-7,12-14 * claims 1, 3, 22-34 * [Y] 8-11; | [XPYI]WO2017059357 (VERTEX PHARMA [US]) [XP] 1,6,7,12-14 * claims 70-74, 1-35, 78, 92-105 * * paragraphs [0059] - [0066] - [ 138] * [Y] 8-11 [I] 2-5 | International search | [Y]US2011159111 (CURRY JAYNE ELIZABETH [GB], et al) [Y] 4, 5 * abstract, para [01117] *; | [XY]WO2015058067 (VERTEX PHARMA [US]) [X] 1-3, 6 * para [0049], [00115], [00126], [00130], [00233], [00237], [00238] * [Y] 4, 5, 7-11; | [Y]US2016045596 (GERETTI ELENA [US], et al) [Y] 7-11* abstract, [0066], [0070] * |